Catecholamine prodrugs for use in the treatment of parkinson's disease

Patent metadata

Field	Value
Publication number	US-11707476-B2
Application number	US-202117386686-A
Country	US
Kind code	B2
Filing date	Jul 28, 2021
Priority date	Nov 24, 2017
Publication date	Jul 25, 2023
Grant date	Jul 25, 2023

Abstract

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

First claim

The invention claimed is:

1. A method for the treatment of a neurodegenerative disease or disorder; which method comprises the administration of a therapeutically effective amount of a compound according to formula (Id)

or a pharmaceutically acceptable salt thereof to a patient in need thereof;
wherein
R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or
R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or
R1 and R2 are both represented by substituent (i) below; or
R1 and R2 are both represented by substituent (ii) below; or
R1 is substituent (i) and R2 is substituent (ii); or
R1 is substituent (ii) and R2 is substituent (i);

wherein * indicates the attachment point; and
wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration.

2. The method according to claim 1 , wherein the neurodegenerative disease or disorder is Parkinson's Disease.

3. The method according to claim 1 , further comprising administering to the patient an additional agent useful in the treatment of the neurodegenerative disease or disorder.

4. The method according to claim 3 , wherein said additional agent is useful in the treatment of Parkinson's disease.

5. The method according to claim 1 , wherein said compound of formula (Id) is the compound represented by formula (Id-ia) below

or a pharmaceutically acceptable salt thereof.

6. The method according to claim 1 , wherein said compound of formula (Id) is the compound represented by formula (Id-ib) below

or a pharmaceutically acceptable salt thereof.

7. The method according to claim 1 , wherein said compound of formula (Id) is the compound represented by formula (Id-iab) below

or a pharmaceutically acceptable salt thereof.

8. The method according to claim 2 , wherein said compound of formula (Id) is the compound represented by formula (Id-ia) below

or a pharmaceutically acceptable salt thereof.

9. The method according to claim 2 , wherein said compound of formula (Id) is the compound represented by formula (Id-ib) below

or a pharmaceutically acceptable salt thereof.

10. The method according to claim 2 , wherein said compound of formula (Id) is the compound represented by formula (Id-iab) below

or a pharmaceutically acceptable salt thereof.

11. The method according to claim 3 , wherein said compound of formula (Id) is the compound represented by formula (Id-ia) below

or a pharmaceutically acceptable salt thereof.

12. The method according to claim 3 , wherein said compound of formula (Id) is the compound represented by formula (Id-ib) below

or a pharmaceutically acceptable salt thereof.

13. The method according to claim 3 , wherein said compound of formula (Id) is the compound represented by formula (Id-iab) below

or a pharmaceutically acceptable salt thereof.

14. The method according to claim 4 , wherein said compound of formula (Id) is the compound represented by formula (Id-ia) below

or a pharmaceutically acceptable salt thereof.

15. The method according to claim 4 , wherein said compound of formula (Id) is the compound represented by formula (Id-ib) below

or a pharmaceutically acceptable salt thereof.

16. The method according to claim 4 , wherein said compound of formula (Id) is the compound represented by formula (Id-iab) below

or a pharmaceutically acceptable salt thereof.

17. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is (4aR,10aR)-1-propyl-6-((triisopropylsilyl)oxy)-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ol.

Assignees

• H Lundbeck As

Inventors

• Jensen Klaus Gjervig
• Kværnø Lisbet
• Jørgensen Morten
• Juhl Martin

Classifications

• A61K31/706 Primary

  containing six-membered rings with nitrogen as a ring hetero atom · CPC title

• A61K31/473 Primary

  ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07D405/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title